Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
Nivolumab-Erhaltung verbessert das Gesamtüberleben bei Patient:innen mit fortgeschrittenem Melanom nach schweren immunvermittelten Nebenwirkungen unter Nivolumab plus Ipilimumab
Journal for ImmunoTherapy of Cancer · 2024-08 · 12 (8) · e009061
DOI: 10.1136/jitc-2024-009061 ↗Auf einen Blick
Bei 122 Patient:innen mit metastasiertem Melanom war die Wiederaufnahme von Nivolumab nach irAE und Immunsuppression mit besserem Gesamtüberleben verbunden. Das Sterberisiko war geringer als ohne Wiederaufnahme.
Fragestellung
Verbessert die Wiederaufnahme von Nivolumab nach einer behandlungsbedingten Unterbrechung wegen irAE unter Ipilimumab/Nivolumab das Überleben?
Methode
Retrospektive Kohortenanalyse von Patient:innen mit Ipilimumab/Nivolumab und irAE mit Therapieunterbrechung und Immunsuppression; multivariate Analyse klinischer Faktoren.
Ergebnisse
Von 165 identifizierten Patient:innen wurden 122 eingeschlossen; 46 nahmen Nivolumab wieder auf. Die Wiederaufnahme war mit besserem Überleben verbunden: HR 0,32 (95 %-KI 0,12–0,84; p=0,02).
Schlussfolgerung der Autor:innen
Die Wiederaufnahme von Nivolumab nach Unterbrechung wegen irAE und abgeschlossener Immunsuppression erhöhte das Gesamtüberleben gegenüber dauerhaftem Absetzen. Die Toxizität nach Wiederaufnahme war beherrschbar.
Kernaussagen
- Wiederaufnahme von Nivolumab war mit besserem Gesamtüberleben verbunden
- HR 0,32 (95 %-KI 0,12–0,84)
- Nach Wiederaufnahme traten 12 weitere irAE auf, 5 Grad 3; keine Grad 4/5
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.08.2024. Verfasst von Anna K Maloney und 11 weiteren Autor:innen. Beteiligte Einrichtung: Quinnipiac University Frank H Netter MD School of Medicine, North Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Melanoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Blitzer Family Fund.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of immunosuppressive agents. There is no data on the impact of resuming nivolumab on survival following recovery from the irAE and completion of immunosuppressive treatment. Patients and methods In this retrospective analysis, we examined a cohort of patients treated with ipilimumab/nivolumab who developed irAEs requiring treatment interruption and immunosuppressive therapy. The differences in physician practice patterns at our institution allowed us to examine the survival effect of restarting single-agent nivolumab. A multivariate analysis of clinical factors associated with improved survival was performed.
Results
We identified 165 patients who were treated with ipilimumab/nivolumab and developed irAEs requiring treatment interruption and immunosuppressive therapy. Patients with the best overall response of progressive disease were excluded. Of the remaining 122 patients, 46 resumed single-agent nivolumab. When stratified by age and adjusted for sex, M-stage, lactate dehydrogenase (LDH), therapy duration, and irAE type, the effect of resumption of nivolumab on survival was highly significant (p=0.02). Patients who resumed nivolumab had a 68% reduction in the hazard of death compared with patients who had not yet or never resumed nivolumab (HR: 0.32, 95% CI: 0.12 to 0.84). Of the patients who resumed nivolumab, 12 (26%) patients had subsequent irAEs, with five patients having grade 3 irAEs. No grade 4 or 5 irAEs were noted.
Conclusions
Resuming single-agent nivolumab following a treatment interruption for ipilimumab/nivolumab-associated irAE and completion of immunosuppressive therapy increased overall survival compared with discontinuing nivolumab permanently in patients with metastatic melanoma. Toxicity observed post-resumption of single-agent nivolumab was manageable with no severe irAEs observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quinnipiac University Frank H Netter MD School of Medicine, North Haven, Connecticut, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA elizabeth_buchbinder@dfci.harvard.edu.
ORCID-Profile: Patrick A Ott, Tamara A Sussman, Ann W Silk, Elizabeth I Buchbinder
Förderung
- Blitzer Family Fund
Zitieren
APA
Maloney, A. K., Giobbie-Hurder, A., Katukota, N., Fogarasi, M. C., Ott, P. A., Hodi, F. S., Sussman, T. A., Silk, A. W., Haq, R., Liu, D., Insco, M., & Buchbinder, E. I. (2024). Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab. Journal for ImmunoTherapy of Cancer, 12(8), e009061. https://doi.org/10.1136/jitc-2024-009061
Vancouver
Maloney AK, Giobbie-Hurder A, Katukota N, Fogarasi MC, Ott PA, Hodi FS, et al. Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab. Journal for ImmunoTherapy of Cancer. 2024;12(8):e009061. doi:10.1136/jitc-2024-009061
BibTeX
@article{Maloney2024,
author = {Maloney, Anna K and Giobbie-Hurder, Anita and Katukota, Nikita and Fogarasi, Miklos C and Ott, Patrick A and Hodi, F Stephen and Sussman, Tamara A and Silk, Ann W and Haq, Rizwan and Liu, David and Insco, Megan and Buchbinder, Elizabeth I},
title = {Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {8},
pages = {e009061},
doi = {10.1136/jitc-2024-009061}
}
EUVIMED